Keith W. Marshall - Jun 2, 2023 Form 4 Insider Report for Prometheus Biosciences, Inc. (RXDX)

Role
Chief Financial Officer
Signature
/s/ Timothy K. Andrews, attorney-in-fact for Keith W. Marshall
Stock symbol
RXDX
Transactions as of
Jun 2, 2023
Transactions value $
$242,302
Form type
4
Date filed
6/2/2023, 07:03 PM
Previous filing
Apr 7, 2023
Next filing
Jun 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXDX Common Stock Options Exercise $242K +78.2K +796.68% $3.10* 88K Jun 2, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXDX Stock Options (Right to Buy) Options Exercise $0 -78.2K -59.67% $0.00 52.8K Jun 2, 2023 Common Stock 78.2K $3.10 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction represents an exercise and hold of stock options by the Reporting Person for tax planning purposes.
F2 25% of the shares subject to the option vested and became exercisable on August 3, 2021, and 1/48th of the shares subject to the option vesting monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date.